CN118159262A - 用于癌症治疗的三剂疗法 - Google Patents

用于癌症治疗的三剂疗法 Download PDF

Info

Publication number
CN118159262A
CN118159262A CN202280069063.5A CN202280069063A CN118159262A CN 118159262 A CN118159262 A CN 118159262A CN 202280069063 A CN202280069063 A CN 202280069063A CN 118159262 A CN118159262 A CN 118159262A
Authority
CN
China
Prior art keywords
cancer
gefitinib
tamoxifen
regimen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280069063.5A
Other languages
English (en)
Chinese (zh)
Inventor
拉里·维森塔尔
威廉·格雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of CN118159262A publication Critical patent/CN118159262A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280069063.5A 2021-09-15 2022-09-15 用于癌症治疗的三剂疗法 Pending CN118159262A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163244412P 2021-09-15 2021-09-15
US63/244,412 2021-09-15
PCT/US2022/043601 WO2023043883A1 (en) 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment

Publications (1)

Publication Number Publication Date
CN118159262A true CN118159262A (zh) 2024-06-07

Family

ID=85603487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280069063.5A Pending CN118159262A (zh) 2021-09-15 2022-09-15 用于癌症治疗的三剂疗法

Country Status (10)

Country Link
US (1) US12611411B2 (https=)
EP (1) EP4401720A4 (https=)
JP (1) JP2024531765A (https=)
KR (1) KR20240060625A (https=)
CN (1) CN118159262A (https=)
AU (1) AU2022345084A1 (https=)
CA (1) CA3231639A1 (https=)
IL (1) IL311229A (https=)
MX (1) MX2024003333A (https=)
WO (1) WO2023043883A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2644194T3 (en) * 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US20100189683A1 (en) 2008-11-14 2010-07-29 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
KR101874390B1 (ko) * 2013-09-26 2018-07-04 파이브3 제노믹스, 엘엘씨 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물

Also Published As

Publication number Publication date
JP2024531765A (ja) 2024-08-29
CA3231639A1 (en) 2023-03-23
EP4401720A4 (en) 2025-07-30
IL311229A (en) 2024-05-01
MX2024003333A (es) 2024-05-20
US20250127791A1 (en) 2025-04-24
WO2023043883A1 (en) 2023-03-23
US12611411B2 (en) 2026-04-28
AU2022345084A1 (en) 2024-03-28
EP4401720A1 (en) 2024-07-24
KR20240060625A (ko) 2024-05-08

Similar Documents

Publication Publication Date Title
Morabito et al. Treatment of small cell lung cancer
RU2662298C2 (ru) Лечение рака комбинацией плинабулина и таксана
WO2021098679A1 (zh) Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
US12102613B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN103153292B (zh) 联合抗癌疗法的组合物
CN109475629A (zh) 用notch和pd-1或pd-l1抑制剂的组合治疗
TW202523284A (zh) 用於治療子宮內膜癌的方法、組成物和組合
CN108135901A (zh) 胆管癌的治疗
KR20190130078A (ko) 항종양 알칼로이드를 이용한 병용요법
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
Wu et al. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
EP3691632B1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
CN120131693A (zh) 一种治疗胰腺癌的药物组合物及其应用
CN118159262A (zh) 用于癌症治疗的三剂疗法
US9415078B2 (en) Method of treating desmocollin-3 expressing cancer with Mycobacterium w
TW201907916A (zh) 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑
TW201834650A (zh) 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途
EP3127544A1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
MX2007000971A (es) Combinaciones de epotilina.
JP2022522994A (ja) がんの処置のための組合せ物
RU2801665C2 (ru) Фармацевтическая комбинация для лечения рака

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination